Voltron Therapeutics, Inc., a Lucius Partners Portfolio Company, Announces Data Demonstrating VaxCelerate Vaccine-Induced Protection Against Viral Pathogens

/PRNewswire/ -- Voltron Therapeutics, a Lucius Partners portfolio company, presented new evidence that demonstrates its VaxCelerate Vaccine platform's...

Related Keywords

Orlando ,Florida ,United States ,Massachusetts ,Delaware ,Patrick Gallagher ,Voltron Vaxcelerate ,Mark Poznansky ,James Ahern ,Immunotherapy Center ,Exchange Commission ,Lucius Partners ,Immunotherapy Center At Massachusetts ,Presentation At Military Health System Research Symposium ,Voltron Therapeutics Inc ,Department Of Defense Do ,Health System Research Symposium ,Papilloma Virus ,Military Health System Research Symposium ,Voltron Therapeutics ,Vaxcelerate Vaccine ,Massachusetts General ,Lassa Fever ,Novel Self Assembling Vaccine ,Inhibits Tumor Growth ,Tumor Model ,Neck Cancer ,Massachusetts General Hospital ,Voltron Therapeutic ,Self Assembling Vaccine ,Emerging Infectious ,Private Securities Litigation Reform Act ,Vaxcelerate Platform ,